What are the side effects of metoclopramide?

Metoclopramide Side Effects

The most critical side effect of metoclopramide is tardive dyskinesia (TD), an irreversible movement disorder that has prompted an FDA black box warning, particularly when used beyond 12 weeks. 1

Serious Neurologic Side Effects

Tardive Dyskinesia (TD)

• Irreversible involuntary movements primarily affecting facial muscles (lip smacking, tongue protrusion, chewing motions, eye blinking) 1
• Risk increases with:
  • Duration of use (especially >12 weeks)
  • Higher cumulative doses
  • Older age, particularly elderly women
  • Diabetes mellitus
  • Patients on psychotropic agents 2
• No effective treatment exists; symptoms may lessen after discontinuation but often persist 1

Acute Extrapyramidal Symptoms (EPS)

• Occur in approximately 9% of pediatric patients (95% CI: 5-17%) 3
• Acute dystonia: Sudden muscle spasms affecting neck, eyes (oculogyric crisis), or torso
  • Usually occurs within first 2 days of treatment
  • More common in children and adults under age 30 1
  • Can be life-threatening (laryngospasm) 4
  • Responds to anticholinergic medications (e.g., trihexyphenidyl) 5
• Akathisia: Severe restlessness, pacing, agitation 2, 1
• Parkinsonism: Tremor, rigidity, bradykinesia 1

Other Serious Neurologic Effects

• Neuroleptic Malignant Syndrome (NMS): Rare but potentially fatal
  • High fever, muscle rigidity, altered mental status, autonomic instability
  • Requires immediate hospitalization 1
• Depression and suicidality: Some patients develop depression with suicidal ideation or complete suicide 1

Common Side Effects

The most frequently reported adverse effects in clinical trials include 2:

• Restlessness, drowsiness, fatigue, dizziness (sedation ~6% in multiple-dose studies)
• Headache
• Confusion
• Insomnia
• Diarrhea (6%, 95% CI: 4-9% in pediatric studies) 3

Gastrointestinal Effects

• Nausea and diarrhea (paradoxically, despite being an antiemetic) 2, 1
• Constipation 1

Other Notable Side Effects

Cardiovascular

• QTc prolongation risk (particularly with domperidone, less so with metoclopramide) 6

Endocrine

• Hyperprolactinemia due to dopamine antagonism 7, 8
• May affect hypothalamic-pituitary-gonadal axis

Metabolic

• Fluid retention (particularly concerning in patients with heart failure or liver disease) 1

Infusion-Related

• When given IV too rapidly: acute anxiety, restlessness followed by sedation 1

Risk Mitigation Strategies

According to the 2025 AGA guidelines 2:

• Discuss potential adverse effects before initiating treatment
• Start at low doses (5 mg PO before meals, titrate to 10 mg if needed)
• Implement drug holidays: 1-4 weeks off every 8-12 weeks
• Assess efficacy and adverse effects at 4-8 weeks
• Monitor continuously for movement disorders throughout treatment
• Limit duration to <12 weeks when possible
• Use extra caution in:
  • Elderly patients (especially women)
  • Patients on psychotropic medications
  • Diabetic patients
  • Children and young adults (<30 years)

Absolute Risk Context

The absolute risk of serious adverse events remains low 2. In clinical trials, metoclopramide showed lower serious adverse event rates compared to placebo (RR 0.64,95% CI: 0.17-2.41), though discontinuation rates were higher (RR 2.15,95% CI: 0.89-5.19), primarily due to GI and neurologic symptoms 2.

Special Populations

Pediatrics

• Higher risk of EPS compared to adults 4, 3
• Dystonia and akathisia most common
• Most adverse effects are reversible and not of long-term significance 3

CYP2D6 Poor Metabolizers

• Increased risk of acute dystonic reactions even after first dose 9
• Consider dose reduction, though pre-emptive genetic testing not currently required 9